Ignite Creation Date:
2024-05-05 @ 6:36 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00511992
Status:
COMPLETED
Last Update Posted:
2017-07-02
First Post:
2007-08-03
Brief Title:
Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer
Sponsor:
University of Oklahoma
Organization:
University of Oklahoma
Study Overview
Official Title:
Phase II Study of Paclitaxel TAXOL Intraperitoneal Cisplatin and IV Avastin Followed by Avastin Consolidation for Advanced Ovarian and Peritoneal Carcinoma or Fallopian Tube Cancer
Status:
COMPLETED
Status Verified Date:
2017-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the tolerability of intraperitoneal cisplatin with intravenous paclitaxel and Avastin as defined by the proportion of patients able to complete 6 cycles of treatment
Detailed Description:
Ovarian cancer is the leading cause of death from gynecologic cancer in the United States The high death rate stems from late presentation and tumor that has spread beyond the ovary at the time of diagnoses
Ovarian cancer typically spreads throughout the peritoneal cavity Three randomized clinical trial have recently demonstrated the superiority of intraperitonealIP over intravenous platinum based chemotherapy in optimally debulked advance ovarian cancer The success of Bevacizumab in metastatic colorectal cancer has led to trials evaluating its efficacy in advanced ovarian cancer Based on the mechanism of action of Bevacizumab there may be benefit of extended therapy with this agent
Ovarian cancer typically spreads throughout the peritoneal cavity Three randomized clinical trial have recently demonstrated the superiority of intraperitonealIP over intravenous platinum based chemotherapy in optimally debulked advance ovarian cancer The success of Bevacizumab in metastatic colorectal cancer has led to trials evaluating its efficacy in advanced ovarian cancer Based on the mechanism of action of Bevacizumab there may be benefit of extended therapy with this agent
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None